CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial Multimodality imaging in cardiology: a statement on behalf of the Task Force on Multimodality Imaging of the European Association of Cardiovascular Imaging High-Risk Coronary Atherosclerosis Is It the Plaque Burden, the Calcium, the Lipid, or Something Else? Basic Biology of Oxidative Stress and the Cardiovascular System: Part 1 of a 3-Part Series The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics The Impact of Proximal Vessel Tortuosity on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Mode of Death in Heart Failure With Preserved Ejection Fraction

Clinical Trial2018 Oct 27. [Epub ahead of print]

JOURNAL:J Am Coll Cardiol. Article Link

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial

M Szarek, HD White, PH Steg, ODYSSEY OUTCOMES Committees and Investigators. Keywords: Alirocumab; acute coronary syndrome; total events

FuLL TEXT PDF